Pfizer and Valneva have announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for their Lyme disease vaccine candidate, VLA15. This step marks a significant milestone in the development of the first potential vaccine aimed at preventing Lyme disease in both adults and children aged five years and older.

The regulatory filing is based on data from the Phase 3 VALOR clinical trial. While the companies have expressed confidence in the vaccine's efficacy and safety profile, the development process has faced scrutiny. During the Phase 3 trial, Pfizer identified a data integrity issue where a significant number of participants were excluded from the per-protocol analysis due to violations of Good Clinical Practice (GCP) at certain trial sites. Pfizer and Valneva maintain that these exclusions did not negatively impact the overall efficacy results of the study, and that the vaccine remains a viable candidate for public health use.

If approved, VLA15 would provide a preventative option for individuals in regions where Lyme disease is endemic. The EMA will now begin its formal review process to determine whether the benefits of the vaccine outweigh the risks associated with its administration. The companies are also preparing for potential regulatory submissions in the United States, pending further discussions with the FDA.